Aptamer Group plc, the developer of novel Optimer ® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease ...

Researchers have figured out a way to make an RNA biosensor that fluoresces when it encounters small inorganic metabolites—not by engineering the RNA but by adjusting its fluorogenic ligand molecule.

Aptamers, nucleic acids capable of selectively binding to viruses, proteins, ions, small molecules, and various other targets, are garnering attention in drug development as potential antibody ...